FOLH1 and neoplasm: Pre-targeting strategies, ligand modification to reduce salivary gland affinity, and tandem therapy regimens (lowering per-cycle [225Ac]Ac-PSMA activity while combining with [177Lu]Lu-PSMA) are also under investigation as methods to limit cumulative glandular dose without compromising tumour control [39].